Brexpiprazole: A Third-Generation Antipsychotic
Time:2025-04-23
Views:4
Brexpiprazole, an atypical antipsychotic, exerts its therapeutic effects through a triple mechanism combining partial agonism at dopamine D2 (Ki=0.30 nM) and serotonin 5-HT1A receptors (Ki=0.12 nM) with antagonism at 5-HT2A receptors. This unique receptor profile enables comprehensive improvement in positive/negative symptoms, cognitive dysfunction, and affective symptoms in schizophrenia. Notably, it is the only antipsychotic in a _Lancet_ meta-analysis of 32 antipsychotics to demonstrate no statistically significant difference in all-side-effect risks compared to placebo.
In 2015, the FDA approved brexpiprazole for the adjunctive treatment of schizophrenia and depression; 2018: brexpiprazole launched in the EU and Japan; 2023: FDA expands indication to Alzheimer‘s disease Treatment of agitation, PTSD, and borderline personality disorder in patients with Alzheimer‘s disease.June 2024 Brexpiprazole was approved for marketing by NMPA (trade name: Rexulti®) The patent for brexpiprazole‘s core compound expires in 2026, and more than thirty domestic pharmaceutical companies have already submitted applications for generic marketing.
In its actual production process, it will involve a variety of brexpiprazole impurities and related research and analysis, some of the impurities are known to include: brexpiprazole impurity 1--50, brexpiprazole sulfoxide, structural warning impurity brexpiprazole nitrogen oxides and so on.
For the needs of pharmaceutical enterprises and quality control, SZEB supplies a suite of Brexpiprazole impurities in stock, providing COA, HPLC/HNMR/mass spectrometry analysis (in line with USP/EP standards), while supporting the structure of nitrosamines, genotoxic impurities + content calibration. One-stop service. For more details, please visit
the official website:https://www.ex-biotech.com/
inquiry hotline: 0755-23051186.
the official website:https://www.ex-biotech.com/
inquiry hotline: 0755-23051186.